Identification of a gene expression core signature for Duchenne Muscular Dystrophy (DMD) via integrative analysis reveals novel potential compounds for treatment

2010 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology, CIBCB 2010

Volumn , Issue , 2010, Pages 82-87

  Ichim Moreno, Norú ^a   Aranda, Manuel ^a   Voolstra, Christian R ^a  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

DATA SETS; GENETIC DISORDERS; GLUCOCORTICOIDS; INTEGRATIVE ANALYSIS; META ANALYSIS; MUSCULAR DYSTROPHY; SIDE EFFECT; SIGNATURE GENES;

ARTIFICIAL INTELLIGENCE; BIOINFORMATICS; DATA PROCESSING; NEUROMUSCULAR REHABILITATION;

GENE EXPRESSION;

EID: 77955608592     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/CIBCB.2010.5510485     Document Type: Conference Paper

References (39)

1. A. E. Emery, "Population frequencies of inherited neuromuscular diseases - a world survey," Neuromuscul Disord, vol. 1, pp. 19-29, 1991.
2. E. P. Hoffman, R. H. Brown, and L. M. Kunkel, "Dystrophin: The protein product of the duchenne muscular dystrophy locus," Cell, vol. 51, pp. 919-928, 1987.
3. M. Koenig, A. P. Monaco, and L. M. Kunkel, "The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein," Cell, vol. 53, pp. 219-228, 1988.
4. B. Mokri and A. G. Engel, "Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. 1975," Neurology, vol. 51, p. 1 and 10 pages following, Jul 1998.
5. V. Straub and K. P. Campbell, "Muscular dystrophies and the dystrophin-glycoprotein complex," Curr Opin Neurol, vol. 10, pp. 168-75, Apr 1997.
6. T. A. Rando, "The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies," Muscle Nerve, vol. 24, pp. 1575-94, Dec 2001.
7. F. Galbiati, et al., "Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities," J Biol Chem, vol. 276, pp. 21425-33, Jun 15 2001.
8. I. Richard, et al., "Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A," Cell, vol. 81, pp. 27-40, Apr 7 1995.
9. Q. L. Lu, et al., "Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse," Nat Med, vol. 9, pp. 1009-14, Aug 2003.
10. K. E. Wells, S. Fletcher, C. J. Mann, S. D. Wilton, and D. J. Wells, "Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle," FEBS Lett, vol. 552, pp. 145-9, Sep 25 2003.
11. S.V. Boehm, P. Constantinou, S. Tan, H. Jin and R. G. Roberts "Profound human/mouse differences in alpha-dystrobrevin isoforms: a novel syntrophin-binding site and promoter missing in mouse and rat," BMC Biology, vol. 7, p. 85, 2009.
12. J. Lamb, et al., "The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease," Science, vol. 313, pp. 1929-1935, September 29, 2006 2006.
13. T. Barrett, et al., "NCBI GEO: archive for high-throughput functional genomic data," Nucl. Acids Res., vol. 37, pp. D885-890, January 1, 2009 2009.
14. M. Bakay, et al., "Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration," Brain, vol. 129, pp. 996-1013, Apr 2006.
15. J. N. Haslett, et al., "Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle," Proc Natl Acad Sci U S A, vol. 99, pp. 15000-5, Nov 12 2002.
16. D. Baban and K. E. Davies, "Microarray analysis of mdx mice expressing high levels of utrophin: Therapeutic implications for dystrophin deficiency," Neuromuscular Disorders, vol. 18, pp. 239-247, 2008.
17. B. S. Tseng, et al., "Regenerated mdx mouse skeletal muscle shows differential mRNA expression," J Appl Physiol, vol. 93, pp. 537-45, Aug 2002.
18. V. G. Tusher, R. Tibshirani and G. Chu, "Significance analysis of microarrays applied to the ionizing radiation response," Proc Natl Acad Sci U S A, vol. 98, pp. 5116-21, Apr 24 2001.
19. R. Chen, L. Li and A. J. Butte, "AILUN: reannotating gene expression data automatically," Nat Methods, vol. 4, p. 879, Nov 2007.
20. G. Wei, et al., "Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance," Cancer Cell, vol. 10, pp. 331-342, 2006.
21. Y. W. Chen, P. Zhao, R. Borup, and E. P. Hoffman, "Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology," J Cell Biol, vol. 151, pp. 1321-36, Dec 11 2000.
22. M. Pescatori, et al., "Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression," FASEB J., vol. 21, pp. 1210-1226, April 1, 2007 2007.
23. P. C. Ortiz-Lazareno, et al., "MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1," Immunology, vol. 124, pp. 534-41, Aug 2008.
24. S. Assereto, et al., "Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment," Am J Physiol Cell Physiol, vol. 290, pp. C577-82, Feb 2006.
25. G. Bonuccelli, et al., "Proteasome Inhibitor (MG-132) Treatment of mdx Mice Rescues the Expression and Membrane Localization of Dystrophin and Dystrophin-Associated Proteins," Am J Pathol, vol. 163, pp. 1663-1675, October 1, 2003 2003.
26. A. C. Allison, R. Cacabelos, V. R. Lombardi, X. A. Alvarez, and C. Vigo, "Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease," Prog Neuropsychopharmacol Biol Psychiatry, vol. 25, pp. 1341-57, Oct 2001.
27. J. H. Lee, et al., "Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid," Biochem Pharmacol, vol. 72, pp. 1311-21, Nov 15 2006.
28. H. Hu, et al., "Celastrol, a Triterpene Extracted From Tripterygium wilfordii Hook F, Inhibits Platelet Activation," Journal of Cardiovascular Pharmacology, vol. 54, pp. 240-245 10.1097/FJC.0b013e3181b21472, 2009.
29. A. R. Baudy, N. Saxena, H. Gordish, E. P. Hoffman, and K. Nagaraju, "A robust in vitro screening assay to identify NF-[kappa]B inhibitors for inflammatory muscle diseases," International Immunopharmacology, vol. 9, pp. 1209-1214, 2009.
30. M. K. Pandey, et al., "Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue," J Biol Chem, vol. 282, pp. 17340-50, Jun 15 2007.
31. Y. Wang, F. L. Chan, S. Chen, and L. K. Leung, "The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase," Life Sciences, vol. 77, pp. 39-51, 2005.
32. A. Y. Manzur, T. Kuntzer, M. Pike, and A. Swan, "Glucocorticoid corticosteroids for Duchenne muscular dystrophy," Cochrane Database Syst Rev, p. CD003725, 2004.
33. A. Y. Manzur, T. Kuntzer, M. Pike, and A. Swan, "Glucocorticoid corticosteroids for Duchenne muscular dystrophy," Cochrane Database Syst Rev, p. CD003725, 2008.
34. R. T. Moxley, 3rd, et al., "Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society," Neurology, vol. 64, pp. 13-20, Jan 11 2005.
35. K. P. C. Araújo, et al., "T.P.4.03 Treatment with Bortezomib (PS-341) of Golden Retriever Muscular Dystrophy (GRMD): Analysis of proteasome inhibition and morphology of dystrophic skeletal muscle," Neuromuscular Disorders, vol. 19, pp. 613-613, 2009.
36. P. C. Mack, A. M. Davies, P. N. Lara, P. H. Gumerlock, and D. R. Gandara, "Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer," Lung Cancer, vol. 41, pp. 89-96, 2003.
37. J. San Miguel, et al., "A practical update on the use of bortezomib in the management of multiple myeloma," Oncologist, vol. 11, pp. 51- 61, Jan 2006.
38. D. C. Hassane, et al., "Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data," Blood, vol. 111, pp. 5654-5662, June 15, 2008 2008.
39. S. Ishiura, I. Nonaka, T. Fujita, and H. Sugita, "Effect of Cycloheximide Administration on Bupivacaine-Induced Acute Muscle Degradation," J Biochem, vol. 94, pp. 1631-1636, November 1, 1983 1983.